Advances in PH Journal
Unlocking New Treatment Benefits and Options in PAH, Spring 2008 (Vol 7, No 1)
- Guest Editor's Commentary
- Editor's Memo
Introducing CME Credit-and More Dynamic Content
- Profiles in PH
David Badesch, MD, Outstanding Researcher, but First to Credit Team of Clinicians and Caregivers
- International Corner
Dr Bob Schilz offered me the chance to review the Winter 2007-2008 issue of Advances in Pulmonary Hypertension. It turned out to be a very interesting experience.
- Evidence-based Medical Management of Pulmonary Hypertension 2008: Review of Updated 2007 ACCP Guidelines
During the past decade remarkable advances have been made in the understanding, diagnosis, and clinical management of pulmonary arterial hypertension (PAH). Each of these issues was carefully addressed in the American College of Chest Physicians (ACCP) guidelines document published in 2004.
- Phase 2 and 3 Clinical Trials in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH), an incurable disease, is characterized by medial hypertrophy, intimal fibrosis, and in situ thrombi in small muscular pulmonary arteries.1 PAH was considered a rapidly fatal illness with a median survival of 2.8 years in the 1980s when no proven therapies were available.
- Combination Therapies in Pulmonary Arterial Hypertension
Despite recent advances in the identification of therapeutic targets and the development of novel medications, pulmonary arterial hypertension (PAH) remains a debilitating and progressive condition.
- Guidelines for the Prevention of Central Venous Catheter- Related Bloodstream Infections with Prostanoid Therapy for Pulmonary Arterial Hypertension
The inception and completion of this document is the work of a collection of dedicated healthcare providers in the field of pulmonary hypertension medicine. It should be used as a guideline for best clinical practice. Every attempt was made to ensure the relevance and timeliness of the information included.
- Pulmonary Hypertension Roundtable Discussion
Are we using PAH-specific therapies in non-WHO group I patients, and if so, how and why are we using them?